(OTCQB: BIXT) (the "Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...

Hawaii airports have a 44% survival rate for cardiac arrests, thanks to AEDs. Free CPR and AED training is available at ...

Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...

Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for ...

In early 2024, the World Health Organization predicted that by 2050 there will be more than 35 million new cancer cases ...

The Million Fruit Trees Plantation (MFTP) project has completed its third phase, generating over Nu 1 million in revenue from ...

The FDA granted orphan drug designation to amezalpat in hepatocellular carcinoma based on phase 1b/2 data showing efficacy ...

A study by Joseph J. Mangano, an epidemiologist with the Radiation and Public Health Project, sheds light on the impact of ...

The epaulette shark’s ability to “walk” on land gives it a distinct survival advantage and traces its lineage back to the ...

Young patients with low-risk, relapsed Hodgkin lymphoma may be able to avoid transplant, data from 3 studies suggest.

The risk for melanoma-related death increased among patients with T1 melanoma tumors thicker than 0.8 mm, according to a study.According to the American Joint Committee on Cancer (AJCC) 8th Edition ...

Mark A. Lewis, MD, discussed the promise of the ESOPEC and TRANSMET trials and the need for their further investigation.